{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T04:05:11Z","timestamp":1771473911034,"version":"3.50.1"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T00:00:00Z","timestamp":1723420800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002998","name":"College ter Beoordeling van Geneesmiddelen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002998","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Regulatory Toxicology and Pharmacology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.yrtph.2024.105682","type":"journal-article","created":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T22:23:55Z","timestamp":1722464635000},"page":"105682","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["The use of weight-of-evidence approaches to characterize developmental toxicity risk for therapeutic monoclonal antibodies in humans without in vivo studies"],"prefix":"10.1016","volume":"152","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3761-8993","authenticated-orcid":false,"given":"Hsiao-Tzu","family":"Chien","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Puck","family":"Roos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frans G.M.","family":"Russel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter T.","family":"Theunissen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter J.K.","family":"van Meer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yrtph.2024.105682_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2022.105327","article-title":"FDA and industry collaboration: identifying opportunities to further reduce reliance on nonhuman primates for nonclinical safety evaluations","volume":"138","author":"Ackley","year":"2023","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"2","key":"10.1016\/j.yrtph.2024.105682_bib4","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.yrtph.2010.10.005","article-title":"Safety evaluation of biological drugs: what are toxicology studies in primates telling us?","volume":"59","author":"Baldrick","year":"2011","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"6","key":"10.1016\/j.yrtph.2024.105682_bib5","article-title":"ICH S1 prospective evaluation study: weight of evidence approach to predict outcome and value of 2-year rat carcinogenicity studies. A report from the regulatory authorities subgroup","volume":"11","author":"Bourcier","year":"2024","journal-title":"Front Toxicol"},{"issue":"6","key":"10.1016\/j.yrtph.2024.105682_bib6","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/bdrb.21089","article-title":"Placental transfer of Fc-containing biopharmaceuticals across species, an industry survey analysis","volume":"98","author":"Bowman","year":"2013","journal-title":"Birth Defects Res B Dev Reprod Toxicol"},{"issue":"4\u20135","key":"10.1016\/j.yrtph.2024.105682_bib7","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/bdrb.21184","article-title":"Goldilocks' determination ofWhat new in vivo data are \u201cjust right\u201d for different common drug development scenarios, Part 1","volume":"107","author":"Bowman","year":"2016","journal-title":"Birth Defects Res B Dev Reprod Toxicol"},{"issue":"1","key":"10.1016\/j.yrtph.2024.105682_bib8","first-page":"10","article-title":"Predictive power of preclinical studies in animals for the immunogenicity of recombinant therapeutic proteins in humans","volume":"6","author":"Bugelski","year":"2004","journal-title":"Curr. Opin. Mol. Therapeut."},{"key":"10.1016\/j.yrtph.2024.105682_bib9","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.reprotox.2020.10.002","article-title":"Knockout mouse models are predictive of malformations or embryo-fetal death in drug safety evaluations","volume":"99","author":"Catlin","year":"2021","journal-title":"Reprod. Toxicol."},{"issue":"2","key":"10.1016\/j.yrtph.2024.105682_bib10","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.yrtph.2011.10.016","article-title":"The design of chronic toxicology studies of monoclonal antibodies: implications for the reduction in use of non-human primates","volume":"62","author":"Chapman","year":"2012","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"6","key":"10.1016\/j.yrtph.2024.105682_bib11","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/bdrb.20216","article-title":"Developmental and reproductive toxicology studies in nonhuman primates","volume":"86","author":"Chellman","year":"2009","journal-title":"Birth Defects Res B Dev Reprod Toxicol"},{"key":"10.1016\/j.yrtph.2024.105682_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2022.105329","article-title":"Re-evaluating the need for chronic toxicity studies with therapeutic monoclonal antibodies, using a weight of evidence approach","volume":"138","author":"Chien","year":"2023","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"6645","key":"10.1016\/j.yrtph.2024.105682_bib16","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1126\/science.adi6512","article-title":"U.S., European researchers face monkey shortage crisis","volume":"380","author":"Grimm","year":"2023","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.yrtph.2024.105682_bib17","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1084\/jem.20050019","article-title":"A critical role for the programmed death ligand 1 in fetomaternal tolerance","volume":"202","author":"Guleria","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.yrtph.2024.105682_bib19","series-title":"International Conference on Harmonization (ICH) Topic S5(R3)","article-title":"ICH S5 (R3) Guideline on detection of reproductive and developmental toxicity for human pharmaceuticals. January","year":"2020"},{"key":"10.1016\/j.yrtph.2024.105682_bib20","year":"2011","journal-title":"ICH guideline S6 (R1) \u2013 preclinical safety evaluation of biotechnology-derived pharmaceuticals, Step 5"},{"issue":"3","key":"10.1016\/j.yrtph.2024.105682_bib23","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/bdrb.20234","article-title":"The cynomolgus monkey as a model for developmental toxicity studies: variability of pregnancy losses, statistical power estimates, and group size considerations","volume":"89","author":"Jarvis","year":"2010","journal-title":"Birth Defects Res B Dev Reprod Toxicol"},{"issue":"1","key":"10.1016\/j.yrtph.2024.105682_bib25","article-title":"A COVID-19 vaccine: big strides come with big challenges","volume":"9","author":"Mellet","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"2","key":"10.1016\/j.yrtph.2024.105682_bib26","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/bdrb.21105","article-title":"Placental transfer of a fully human IgG2 monoclonal antibody in the cynomolgus monkey, rat, and rabbit: a comparative assessment from during organogenesis to late gestation","volume":"101","author":"Moffat","year":"2014","journal-title":"Birth Defects Res B Dev Reprod Toxicol"},{"issue":"4","key":"10.1016\/j.yrtph.2024.105682_bib30","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/bdrb.20201","article-title":"An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies","volume":"86","author":"Pentsuk","year":"2009","journal-title":"Birth Defects Res B Dev Reprod Toxicol"},{"issue":"5","key":"10.1016\/j.yrtph.2024.105682_bib32","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1600-0684.1997.tb00222.x","article-title":"Frequency of spontaneous congenital defects in rhesus and cynomolgus macaques","volume":"26","author":"Peterson","year":"1997","journal-title":"J. Med. Primatol."},{"key":"10.1016\/j.yrtph.2024.105682_bib34","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.yrtph.2018.07.006","article-title":"Applying a weight of evidence approach to the evaluation of developmental toxicity of biopharmaceuticals","volume":"98","author":"Rocca","year":"2018","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"5","key":"10.1016\/j.yrtph.2024.105682_bib36","doi-asserted-by":"crossref","first-page":"810","DOI":"10.4161\/mabs.25234","article-title":"Immunogenicity of mAbs in non-human primates during nonclinical safety assessment","volume":"5","author":"van Meer","year":"2013","journal-title":"mAbs"},{"issue":"4","key":"10.1016\/j.yrtph.2024.105682_bib38","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/bdrc.20220","article-title":"The enhanced pre- and postnatal study for nonhuman primates: update and perspectives","volume":"93","author":"Weinbauer","year":"2011","journal-title":"Birth Defects Res C Embryo Today"}],"container-title":["Regulatory Toxicology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230024001235?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230024001235?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T10:59:13Z","timestamp":1725361153000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0273230024001235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":22,"alternative-id":["S0273230024001235"],"URL":"https:\/\/doi.org\/10.1016\/j.yrtph.2024.105682","relation":{},"ISSN":["0273-2300"],"issn-type":[{"value":"0273-2300","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The use of weight-of-evidence approaches to characterize developmental toxicity risk for therapeutic monoclonal antibodies in humans without in vivo studies","name":"articletitle","label":"Article Title"},{"value":"Regulatory Toxicology and Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yrtph.2024.105682","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"105682"}}